Antagonists targeting the immune checkpoints CTLA-4 and programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1) have achieved satisfactory results in a large number of clinical trials and appear to induce long-lasting responses that benefit overall survival (OS) in BC (9). This evidence concerns the gene PDCD1 and breast cancer.